Standard Biotools Inc
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -9.0% | -17.4% | -6.2% | +5.7% | -12.8% | +22.6% | -15.3% | +41.8% | -17.2% | +89.5% | -7.3% | |
| – | -7.6% | -32.9% | -1.9% | +34.1% | -24.4% | +22.4% | -38.8% | +189.8% | -24.2% | +137.6% | +20.9% | |
| – | -13.6% | +20.4% | +65.7% | +64.3% | -77.3% | +216.3% | -58.5% | +185.8% | -36.4% | +222.5% | -29.1% | |
| – | -17.6% | -37.4% | +6.2% | +51.1% | -38.5% | +16.9% | -58.5% | +482.7% | -30.7% | +154.9% | -36.0% | |
| – | +13.7% | -42.6% | +3.0% | +10.6% | +14.0% | +33.9% | -27.9% | -5.7% | +13.8% | +70.9% | -60.0% | |
| – | +12.1% | +12.2% | -25.0% | -13.8% | +6.8% | +41.8% | +5.8% | +3.1% | -4.4% | +98.4% | -51.0% | |
| – | – | – | -25.6% | -28.3% | +46.4% | +330.8% | +17.1% | -8.6% | – | – | – | |
| – | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +2.4% | -0.2% | -0.1% | +0.1% | +4.7% | – | |
| – | -10.9% | -12.4% | -14.0% | -16.3% | -14.4% | -14.1% | -33.9% | -54.9% | -88.9% | +1,968.1% | – | |
| – | -0.4% | -1.2% | +1.3% | -9.7% | -52.0% | +67.0% | -2.7% | +161.2% | -0.1% | -70.2% | +2.0% | |
| – | +2.4% | -1.9% | +13.5% | +12.3% | -12.7% | +65.3% | -8.6% | -12.4% | +151.7% | -39.7% | +64.4% | |
| – | – | – | – | – | – | +62.2% | +232.7% | -41.7% | +1,007.6% | -90.2% | -11.8% | |
| – | +3.0% | -34.9% | +6.2% | -4.4% | +27.9% | +79.0% | +15.0% | -25.4% | +16.7% | +33.0% | -56.0% | |
| – | – | – | +0.1% | -11.9% | -68.7% | +0.7% | +18.4% | -2.2% | -93.7% | -92.5% | +0.0% | |
| – | -23.6% | -53.7% | -41.9% | +133.1% | +113.0% | -9.5% | -32.0% | -186.1% | – | – | -10.1% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +3.4% | +1.0% | +13.7% | +20.2% | +68.4% | +7.9% | +5.2% | +3.3% | +1.1% | +345.5% | +8.2% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.